Track topics on Twitter Track topics that are important to you
I-Mab Biopharma, a Shanghai company focused on immuno-oncology and autoimmune diseases, dosed the first patient in a Phase II Taiwan trial of a CD38 antibody in patients with relapsed or refractory multiple myeloma. In 2017, I-Mab acquired greater China rights to TJ202/MOR202 from MorphoSys AG in a $120 million deal. The multi-center trial, which will also include mainland China sites, is designed to lead to a biologics license application in greater China. The start of the trial triggers a $5 million milestone from I-Mab to MorphoSys. More details....
Stock Symbol: (FSE: MOR)
Share this with colleagues:
Original Article: I-Mab Starts Greater China Trials of CD38 Antibody for MyelomaNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...